Supplemental iron: A key to optimizing the response of cancer-related anemia to rHuEPO?

Oncologist

Volumn 3, Issue 4, 1998, Pages 275-278

  Henry, David H ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Anemia; Intravenous iron; Iron deficiency; Recombinant human erythropoietin (rHuEPO); RHuEPO resistance; Serumferritin; Transferrin saturation

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOKINE; ERYTHROPOIETIN; FERRITIN; HEMOGLOBIN; IRON; IRON DEXTRAN; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN;

ANEMIA; CANCER RISK; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; DRUG SAFETY; ERYTHROPOIESIS; HUMAN; INCIDENCE; INTRAVENOUS DRUG ADMINISTRATION; IRON DEFICIENCY; IRON OVERLOAD; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; RETICULOCYTE COUNT; REVIEW; TRANSFUSION; TREATMENT OUTCOME;

EID: 0031713670     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.3-4-275     Document Type: Review

References (13)

1. Eschbach JW, DeOreo P, and the NKF-DOQI Anemia Work Group. NKF-DOQI™ Clinical Practice Guidelines for the treatment of anemia of chronic renal failure. Am J Kidney Dis 1997;30(suppl 3):S129-S140.
2. Cartwright GE. The anemia of chronic disorders. Semin Hematol 1966;3:351-375.
3. Spivak JL. Cancer-related anemia: its causes and characteristics. Semin Oncol 1994;21(suppl 3):3-8.
4. Reed WR, Hussey DH, DeGowin RL. Implications of the anemia of chronic disorders in patients anticipating radiotherapy. Am J Med Sci 1994;308:9-15.
5. Jelkmann W, Wolff M, Fandrey J. Modulation of the production of erythropoietin by cytokines. In vitro studies and their clinical implications. Contrib Nephrol 1990;87:68-77.
6. Faquin WC, Schneider TJ, Goldberg MA. Effect of inflammatory cytokines on hypoxia-induced erythropoietin production. Blood 1992;79:1987-1994.
7. Lee GR. The anemia of chronic disorders. In: Lee OR, Bithell TC, Foerster J et al., eds. Wintrobe's Clinical Hematology, 9th ed. Philadelphia: Lea & Febiger, 1993:840-851.
8. Ludwig H, Fritz E, Leitgeb C et al. Erythropoietin treatment for chronic anemia of selected hematological malignancies and solid tumors. Ann Oncol 1993;4:161-167.
9. Erslev AJ. Clinical manifestations and classification of erythrocyte disorders. In: Beutler E, Lichtman MA, Coller BS et al., eds. Williams Hematology, 5th ed. New York, NY: McGraw-Hill, Inc., 1995:441-447.
10. Lee GR. Iron deficiency and iron deficiency anemia. In: Lee GR, Bithell TC, Foerster J et al., eds. Wintrobe's Clinical Hematology, 9th ed. Philadelphia: Lea & Febiger, 1993:808-839.
11. Henry DH, Abels RI. Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: results of double-blind and open-label follow-up studies. Semin Oncol 1994;21(suppl 3):21-28.
12. Eschbach JW. The anemia of chronic renal failure: pathophysiology and the effects of recombinant erythropoietin. Kidney Int 1989;35:134-138.
13. Van Wyck DB, Stivelman JC, Ruiz J et al. Iron status in patients receiving erythropoietin for dialysis-associated anemia. Kidney Int 1989;35:712-716.